 ISELIN, N.J., Sept. 26, 2022 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will present at Eyecelerator AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois. 